🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to researchers.

An International Health Concern

Gonorrhoea infections are escalating around the world, with estimates suggesting over 82 million new cases per year. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, the spread of superbugs and the highly restricted therapeutic options currently available.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts hope that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This drug, which is also used to treat urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This milestone represents a significant shift in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Testing Results and Worldwide Availability

According to data detailed in a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which uses two antibiotics. The study included nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Medical professionals directly involved have expressed hope. Access to a single-dose, oral treatment like this is seen as a "critical tool" for public health efforts. This is considered crucial to lessen the impact of the infection for patients and to prevent the spread of untreatable gonorrhoea globally.